Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma

CPT: Pharmacometrics and Systems Pharmacology - United States
doi 10.1002/psp4.12482
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

British Journal of Haematology
Hematology
2018English

Polatuzumab Vedotin: First Global Approval

Drugs
Pharmacology
2019English

Epidemiology of Chemotherapy-Induced Anemia in Patients With Non-Hodgkin Lymphoma

Permanente journal,The
Medicine
2019English

Patient-Reported Outcomes of Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large-Cell Lymphoma

OncoTargets and Therapy
OncologyPharmacology
2016English

Non-Hodgkin Lymphoma

2020English

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Polatuzumab Vedotin (Pola) + Obinutuzumab (G) + Lenalidomide (Len) in Patients (Pts) With Relapsed/Refractory (R/R) Follicular Lymphoma (Fl): Phase Ib/Ii Interim Analysis

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Correction To: Polatuzumab Vedotin: First Global Approval

Drugs
Pharmacology
2019English

Longitudinal Risk of Herpes Zoster in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy: A Nationwide Population-Based Study

Scientific Reports
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy